Buyout Desk
Merger

Shore Capital-backed Everis Medical combines with Hemostasis

Everis Medical combines with Hemostasis, a St. Paul, Minnesota maker of chitosan-based sinus dressings and surgical hemostats; terms were not disclosed.

Merger party
Hemostasis
Merger partner
Everis Medical
Status
Completed

Everis Medical, an otolaryngology and head and neck surgery device company backed by Shore Capital Partners, has combined with Hemostasis, LLC. The combined company will operate as Everis Medical, and Everis describes the transaction as its sixth since 2019. The purchase price was not disclosed.

Hemostasis is an innovator in advanced sinus dressings and surgical hemostats, based in St. Paul, Minnesota. Its chitosan-based platform will join Everis' portfolio, which covers repair and reconstruction, hemostasis, post-operative healing and infection management for sinus and nasal surgery.

Kevin McLeod, founder and CEO of Everis Medical, said Hemostasis has built a proprietary technology platform that surgeons trust. Don Pierce, a partner at Shore Capital Partners and chairman of the Everis board, said the combination is the kind of step the partnership was designed to support. Hemostasis' St. Paul facility will continue to develop and manufacture the platform, and its products will keep their existing brand names.

Background

Business
Maker of chitosan-based sinus dressings and surgical hemostats, with a manufacturing and development facility in St. Paul, Minnesota
Deal type
Merger
Headquarters
St. Paul, Minnesota

Sources

Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.

Shore Capital Partners deal history